Marico’s investment case rests on three features: a dominant, cash-generative core (Parachute), a diversification engine that is lifting the share of foods and premium personal care, and a capital-light model that converts most of its profit into cash. The same features explain why the stock commands a premium multiple, and why a strict intrinsic-value framework looks demanding when set against it.

The growth story is clearer in volumes than in rupees. FY26 revenue growth of 26% was inflated by price increases passed on while copra was at record levels, and margins fell nearly 270 basis points as a result. FY27 is the mirror image: revenue growth has moderated to a still-healthy 13% in Q2, but India volumes are growing at 10-11%, gross margin has expanded sharply and EBITDA is rising faster than sales. Operating cash flow of ₹2,084 crore in FY26 (about 1.2x profit) and a net-cash balance sheet confirm that earnings are cash-backed, with only about ₹319 crore of capex needed to run the business.

The DCF translates Marico’s growth into a value of ₹340 per share, far below the market price. The reason is structural rather than a sign of weak performance: the model gives credit for about 15% revenue growth in FY27E fading to single digits, a margin recovery to 19.5% and cash conversion near 70% of EBITDA, yet about 58% of the equity value still sits in the terminal value, and a 12% discount rate is high for a business with negligible debt and a very low share-price beta. Even the most generous corner of the grid (11% WACC, 6% terminal growth) reaches only ₹451, which means the market is capitalising either a much lower discount rate or a longer period of double-digit compounding than the standard framework assumes. The DCF is therefore treated as a conservative anchor and carries a 30% weight.

At ₹878 the stock trades at about 51x FY27E and 44x FY28E earnings, roughly 2.8 times its expected three-year earnings growth (EPS CAGR of about 18% from FY26 to FY29E). Marico deserves a premium to the staples median because its earnings are growing about twice as fast as the large, slower peers and its return on capital is above 40%. Even so, applying the peer median to FY27E earnings, and Marico’s own five-year average multiple (47.7x, per Nirmal Bang) to trailing earnings, yields about ₹750, roughly 15% below the CMP. The re-rating that followed Q2 appears to have moved the stock from the middle of its historical range to its upper end.

Marico’s balance sheet is a poor guide to its worth. Its brands, distribution network and coconut-sourcing relationships are not carried at market value, fixed assets are modest (capex was under ₹350 crore in FY26) and returns on equity are close to 40%, so book value of ₹32 per share represents a floor rather than a fair-value estimate. The method is therefore shown for completeness and weighted at only 5%.

EPV asks what the business would be worth if today’s earnings simply continued with no growth. At about ₹137 per share, it indicates that roughly 85% of the market price represents the value of future growth rather than current earning power. For a company growing volumes at 10% with expanding margins that is not unusual, but it also shows how much of the valuation depends on delivery. EPV carries a 5% weight because it ignores Marico’s growth runway.

The SOTP separates three engines with different growth and risk profiles. The India core earns the highest margins and is valued like a premium staples franchise; the newer foods, premium personal care and digital-first brands are valued on sales because they are still scaling and spending heavily on brand-building; and international, which carries Bangladesh’s currency and inflation risk alongside fast-growing Vietnam and MENA, receives a lower multiple. Segment revenue splits are Zumedha estimates based on reported India and international sales and management’s stated portfolio mix; segment EBITDA allocations are analyst assumptions reconciled to consolidated guidance. The resulting ₹793 per share is the closest of the five methods to the market price because it borrows market multiples, and it carries a 25% weight.

News and sentiment overlay. Positives: Q2 FY27 delivered a 27% EBITDA rise and the highest India profit growth in 51 quarters; FY27 EBITDA growth guidance was raised to the mid-twenties from about 20%; the ₹20,000 crore revenue goal is now targeted for FY29 rather than FY30; copra remains about 35% below its peak; and most brokerages raised targets after the results (Jefferies ₹1,035, Motilal Oswal ₹975, Nirmal Bang ₹970, Morgan Stanley ₹954), with CLSA upgrading to Hold at ₹737. Negatives: crude-linked packaging and derivative costs are elevated with Brent near $105 amid Strait of Hormuz disruption; Saffola edible-oil volumes fell by a high single-digit rate during supply rationalisation; Bangladesh grew only 5% in constant currency; rural demand and El Niño remain a concern; and the stock jumped about 10% in a day to near its 52-week high. Because the upgraded guidance is already embedded in the FY27E and FY28E estimates, only a modest net premium of +2% is applied to the weighted value.

A complete named top-10 institutional table could not be sourced reliably, so only the holders confirmed in public aggregator data are listed above, and the list should be treated as partial rather than a ranked top 10. Figures may lag the live quarter and are entity-level, not scheme-wise; BSE and NSE shareholding filings carry the scheme-wise and FPI-wise detail.